Pergolide Mesylate Tablets

1. Pharmacological studies Pergolide is a typical central nervous system postsynaptic dopamine receptor agonist, which can significantly inhibit the release of prolactin from the anterior pituitary gland, reduce the serum prolactin content of normal and reserpine rats; reduce the metabolic conversion of dopamine in the rat brain, thereby reducing the content of 3,4-dihydroxyphenylacetic acid in the brain, and cause rats with nigrostriatal damage to produce contralateral rotation reactions; increase the autonomous activity and climbing behavior of mice, cause stereotyped animals in rats and guinea pigs, and counteract spontaneous tremors caused by ventral damage to the midbrain dorsal cover of monkeys. 2. Toxicity studies Acute toxicity Female mice oral LD50 is 81.8mg/kg, and male mice oral LD50 is 6.17mg/kg. The long-term toxicity test of rats after oral administration for 6 months showed that this product can cause a dose-dependent increase in autonomous activity and irritability, slow down the rate of weight gain, and significantly increase the weight of the ovaries of female mice. After administration, the rate of weight gain and the weight of the ovaries returned to normal. This product has no significant effect on rats' hematology, blood biochemistry, and other organs and tissue virology indicators. Dogs were given oral administration for three months without obvious toxic reactions. Microbial reverse mutation test, mouse micronucleus test, and in vitro cultured human lymphocyte chromosome aberration test showed that this product had no mutagenic effect. This product did not cause teratogenic effects in mice during the teratogenic sensitive period.

The main ingredient of this product is pergolide mesylate. Molecular weight: C19H26N2S·CH3SO3H

This product is white tablets.

This product is a dopamine receptor agonist and a synergistic drug for compound levodopa preparations. It is suitable for: 1. Patients with Parkinson's disease and Parkinson's syndrome whose compound levodopa preparations have reduced efficacy or motor dysfunction. 2. Hyperprolactinemia.

Oral. 1. Parkinson's disease: The initial dose is 0.05 mg/day, maintained for 2-3 days; then gradually increase the dose under the guidance of a doctor, increasing by 0.05 mg each time, until the optimal effective dose is reached, and the maximum can be increased to 0.2 mg/day, or follow the doctor's advice. 2. Hyperprolactinemia: The initial dose is 0.025-0.05 mg/day, and the dose is adjusted every 2 weeks, the maximum is 0.1-0.15 mg/day, or follow the doctor's advice.

Adverse reactions such as insomnia, vomiting, dizziness, fatigue, nasal congestion, skin itching, and constipation may occur. If the adverse reactions are serious, the drug must be discontinued. According to foreign literature reports, some patients have experienced mental symptoms and positional hypotension after taking this product orally; some patients have sinus tachycardia with atrial premature beats.

People who are allergic to this product or other ergot derivatives.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

If used with other drugs, drug interactions may occur. Please consult your doctor or pharmacist for details.

Store in a cool, dry place.

0.25mg*30s

24 months